Vir gains a partner to pursue 3 cancer drug candidates and about $25 million from Gilead. The share sale gives up some ownership, but the partnership and funding support Vir despite uncertain drug development.
The cancer drug work could give Vir new programs to pursue, and Gilead's share purchase brings Vir about $25 million. Vir is issuing new shares, and the drug candidates may not succeed. The partnership and added cash still support Vir's outlook.
Gilead agreed to work with Vir on 3 possible cancer drugs and buy Vir shares. The filing reports no results or expected value from the drug work, so it does not show a clear change to Gilead's outlook.
Follow Vir Biotechnology, Inc. (VIR) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for VIR